Key facts
- Medibiofarma’s last known valuation is $620K (Jan 2025).
- It has raised $7.8M; the latest was Later Stage VC ($80K) in Jan 2025.
- Notable investors include INNVIERTE SICC, Inveready Asset Management, European Regional Development Fund (Brandenburg), Sociedad de Desarrollo de Navarra, Crohn's & Colitis Foundation — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Medibiofarma
- ·The full record, as it builds
Funding rounds
No funding rounds for Medibiofarma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Medibiofarma
Developer of small molecule drugs designed to treat cancer and non-cancer diseases, and offers treatments to patients suffering from conditions such as cancer, cognitive decline, and fibrosis. The company's drugs are used in immuno-oncology treatments for T-cell infiltration, specifically through the activation of the immune system, enabling healthcare providers to make disease-modifying treatments available to patients with serious or life-threatening conditions.
- Sector
- Healthcare
- HQ
- Barcelona, Spain
- Founded
- 2016
- Employees
- 10
- Website
- medibiofarma.com/
- Ownership
- Privately Held (backing)
Medibiofarma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Medibiofarma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Medibiofarma in its N-PORT filings yet. We sweep new filings monthly.